What Is Semax?
Semax is a synthetic heptapeptide (7 amino acids) analog of ACTH(4-7) with a Pro-Gly-Pro C-terminal extension that enhances metabolic stability. Developed at the Institute of Molecular Genetics (Russian Academy of Sciences), it has been approved as a prescription drug in Russia and several CIS countries since 2001.
Investigated Mechanisms
- BDNF expression — Brain-Derived Neurotrophic Factor, critical for neuron survival and synaptic plasticity
- NGF expression — Nerve Growth Factor, involved in neuron development and maintenance
- Serotonergic system — modulation of tryptophan hydroxylase and serotonin metabolites
- Dopaminergic system — influence on tyrosine hydroxylase expression
Important Notes
Semax is not FDA-approved in the United States. While it holds regulatory approval in Russia for cerebrovascular conditions, the clinical data from Russian studies has not undergone the FDA's drug approval process. It has no approved therapeutic indication in Western countries.
Cited Sources
- According to Dolotov, O.B. et al. (2006). "Semax, an analogue of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression." Brain Research, 1117(1), 54-60. [PubMed]
- According to Filippenkov, I.B. et al. (2020). "Semax neuroprotective effects: transcriptome analysis." BMC Genomics, 21, 402. [PubMed]